See more : eFUEL EFN CORPORATION (EFLN) Income Statement Analysis – Financial Results
Complete financial analysis of Altamira Therapeutics Ltd. (CYTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Altamira Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Catalyst Media Group plc (CMX.L) Income Statement Analysis – Financial Results
- Fineland Living Services Group Limited (9978.HK) Income Statement Analysis – Financial Results
- Reviva Pharmaceuticals Holdings, Inc. (RVPH) Income Statement Analysis – Financial Results
- Molecule Holdings Inc. (EVRRF) Income Statement Analysis – Financial Results
- Upsales Technology AB (publ) (UPSALE.ST) Income Statement Analysis – Financial Results
Altamira Therapeutics Ltd. (CYTO)
About Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 305.62K | 63.88K | 174.48K | -56.00K | 1.27M | 322.00K | -414.00K | -67.00K | 3.01M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.44M | 2.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -1.14M | -2.18M | 174.48K | -56.00K | 1.27M | 322.00K | -414.00K | -67.00K | 3.01M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -372.44% | -3,407.33% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 3.04M | 19.68M | 8.94M | 2.86M | 3.33M | 6.69M | 19.21M | 24.78M | 26.54M | 17.70M | 13.25M | 3.99M |
| General & Administrative | 3.09M | 3.52M | 4.90M | 2.59M | 3.93M | 4.26M | 5.15M | 5.41M | 4.34M | 4.49M | 1.31M | 589.53K |
| Selling & Marketing | 15.35K | 2.38M | 1.50M | 95.66K | 113.96K | 43.82K | 199.48K | 45.65K | 72.56K | 237.72K | 479.03K | 86.23K |
| SG&A | 3.12M | 5.90M | 6.39M | 2.59M | 3.93M | 4.26M | 5.15M | 5.41M | 4.34M | 4.49M | 1.31M | 589.53K |
| Other Expenses | 0.00 | -586.73K | -409.93K | 0.00 | 0.00 | 215.72K | 87.59K | 34.06K | 62.20K | 73.43K | 49.42K | 34.28K |
| Operating Expenses | 6.54M | 24.99M | 14.92M | 5.46M | 7.26M | 10.95M | 24.36M | 30.22M | 30.88M | 22.19M | 14.62M | 4.61M |
| Cost & Expenses | 6.54M | 26.44M | 17.16M | 5.46M | 7.26M | 10.95M | 24.36M | 30.22M | 30.88M | 22.19M | 14.62M | 4.61M |
| Interest Income | 730.20K | 969.00 | 3.22K | 258.00 | 17.88K | 0.00 | 53.57K | 67.57K | 37.00K | 52.13K | 74.04K | 5.83K |
| Interest Expense | 0.00 | 911.87K | 189.70K | 135.15K | 28.63K | 1.07M | 1.64M | 828.55K | 8.00K | 49.64K | 50.18K | 0.00 |
| Depreciation & Amortization | 5.92M | 118.89K | 76.36K | 20.04K | 30.82K | 72.71K | 122.78K | 97.60K | 92.78K | 73.98K | 37.52K | 9.24K |
| EBITDA | -1.35M | -17.64M | -6.72M | -5.26M | -7.24M | -10.95M | -24.31M | -30.06M | -30.84M | -22.19M | -14.51M | -4.60M |
| EBITDA Ratio | 0.00% | -8,511.54% | -26,643.21% | -3,027.89% | 12,930.83% | -865.25% | -7,548.97% | 7,260.41% | 46,031.34% | -737.55% | 0.00% | 0.00% |
| Operating Income | -5.92M | -26.13M | -17.10M | -5.28M | -7.26M | -10.95M | -24.36M | -30.22M | -30.88M | -22.19M | -14.62M | -4.61M |
| Operating Income Ratio | 0.00% | -8,550.76% | -26,767.78% | -3,028.04% | 12,962.76% | -865.25% | -7,565.61% | 7,300.31% | 46,086.57% | -737.59% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.35M | -645.64K | -1.46M | -2.94M | 433.41K | -380.10K | -66.00K | -570.03K | 1.17M | 4.01M | -82.89K | 8.09K |
| Income Before Tax | -7.27M | -26.54M | -17.37M | -8.22M | -6.83M | -11.33M | -24.43M | -30.79M | -29.71M | -18.19M | -14.70M | -4.60M |
| Income Before Tax Ratio | 0.00% | -8,683.69% | -27,188.48% | -4,712.11% | 12,188.82% | -895.28% | -7,586.10% | 7,438.00% | 44,335.82% | -604.35% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -10.33K | 21.62K | -21.28K | -193.84K | 162.18K | -17.77K | -131.06K | -84.78K | -892.18K | 305.75K | 0.00 |
| Net Income | -7.27M | -26.53M | -17.39M | -8.20M | -6.63M | -11.50M | -24.41M | -30.66M | -29.71M | -18.19M | -15.00M | -4.60M |
| Net Income Ratio | 0.00% | -8,680.31% | -27,222.33% | -4,699.91% | 11,842.68% | -908.09% | -7,580.58% | 7,406.34% | 44,335.82% | -604.35% | 0.00% | 0.00% |
| EPS | -14.81 | -582.58 | -525.13 | -545.41 | -455.96 | -2.89K | -22.32K | -35.73K | -36.79K | -26.27K | -33.25K | -10.20K |
| EPS Diluted | -14.80 | -582.58 | -525.13 | -545.41 | -455.96 | -2.89K | -22.32K | -35.73K | -36.79K | -26.27K | -33.25K | -10.20K |
| Weighted Avg Shares Out | 491.00K | 45.54K | 33.12K | 15.04K | 14.55K | 3.98K | 1.09K | 858.20 | 807.40 | 692.30 | 451.30 | 451.30 |
| Weighted Avg Shares Out (Dil) | 491.26K | 45.54K | 33.12K | 15.04K | 14.55K | 3.98K | 1.09K | 858.20 | 807.40 | 692.30 | 451.30 | 451.30 |
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced that it will host its First Half of 2023 Financial...
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will...
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia
HAMILTON, BERMUDA, July 20, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it has entered into an exclusive agreement with...
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal
HAMILTON, BERMUDA, July 17, 2023 (GLOBE NEWSWIRE) -- -Detailed results from house dust mite trial published in Clinical and Translational Allergy -Study demonstrates statistically significant alleviation of nasal symptoms of allergic rhinitis
Best Penny Stocks Today? 3 Under $1 To Watch Now
If you're looking for the best penny stocks to buy today, you should be well-prepared to deal with high volatility. Whether it's the latest debt ceiling crisis, pandemic fear reemerging, today's Fed meeting minutes from May, or speeches by Janet...
Sphere Fluidics Updates Brand Identity to Align With Ambitious, Global Commercial Growth Strategy
CAMBRIDGE, England--(BUSINESS WIRE)--Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the introduction of new branding to align with its ambitious global commercial growth strategy. The update has been introduced to better...
Altamira Therapeutics Ltd. (CYTO) Q4 2022 Earnings Call Transcript
Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q4 2022 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Thomas Meyer - Founder, Chairman and Chief Executive Officer Covadonga Pañeda - Chief Operating Officer Conference Call Participants Operator Good morning, and...
Ozette Announces New Suite of Machine Learning-Powered Computational Analysis Solutions Coupled with High Dimensional Full Spectrum Cytometry Data Generation to Accelerate Decision-Making for Clinical Biomarker Teams
SEATTLE--(BUSINESS WIRE)--Ozette Technologies, Inc., a technology-driven life sciences company, announces the launch of their Assay-to-Insights product, a streamlined, state-of-the-art process to explore the immune system in fresh and frozen samples. Ozette Assay-to-Insights combines three technologies developed by the company: world-class...
Deepcell Launches AI-Powered Single Cell Analysis Platform to Accelerate Cell Biology Discovery and Catalyze Field of Morpholomics
MENLO PARK, Calif.--(BUSINESS WIRE)--Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the launch of the REM-I Platform, a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument,...
3 Tips for Day Trading Penny Stocks in 2023
Use these tips to day trade penny stocks in 2023 The post 3 Tips for Day Trading Penny Stocks in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports